High flow nasal cannula vs face mask

1.Sohrabi C, Alsafi Z, O'Neill N, Khan M, Kerwan A, Al-Jabir A, et al. The World Health Organization declares a global emergency: an overview of the new coronavirus 2019 (COVID-19). Int J Surg. 2020;76:71-6. PubMed PubMed Central Google Scholar 2.Truog RD, Mitchell C, Daley GQ. The most difficult sorting – the allocation of fans in a pandemie. N Engl J Med. 2020. PubMed Google Scholar 3.Wu Z, McGoogan JM. Characteristics and important lessons from the 2019 coronavirus outbreak (COVID-19) in China: summary of the report on 72,314 cases from china's Centers for Disease Control and Prevention. Yama. 2020;323(13):1239–42. Article PubMed PubMed Central Google Scholar 4.Wang K, Kang S, Tian R, Zhang X, Zhang X, Wang Y. Imaging and diagnostic value of CT of chest coronavirus disease 2019 (COVID-19) in the Xiaogan region. Clin Radiol. 2020. PubMed Central Google Scholar 5.Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving sepsis campaign: guidelines for managing critically ill adults with coronary disease 2019 (COVID-19). Crit Care Med. 2020. PubMed PubMed Central Google Scholar 6.Hui DS, Chow BK, Lo T, Tsang OTY, Ko FW, Ng SS, et al. Exhaled air dispersion during treatment with high flow nasal cannulas compared to CPAP through various masks. Eur Respir J. 2019;53(4):1802339.CAS Article by Google Scholar 7.Loh NW, Tan Y, Taculod J, Gorospe B, Teope AS, Somani J, et al. The effect of high-flute nasal cannulas (HFNC) on the distance of coughing: consequences on its use during a new outbreak of coronavirus disease. Can J Anaesth. 2020. PubMed Central Google Scholar 8.Frat JP, Thille AW, Mercat A, Girault C, Ragot S, Perbet S, et al. Oxygen with high nasal cannula flow in acute hypoxemic respiratory failure. N Engl J Med. 2015;372(23):2185-96.CAS Article Google Scholar 9.Lee CC, Mankodi D, Shaharyar S, Ravindranathan S, Danckers M, Herscovici P, et al. High nasal cannula flow versus conventional oxygen therapy and non-invasive ventilation in adults with acute hypoxemic respiratory failure: a systematic review. Respir Med. 2016;121:100-8.Article by Google Scholar 10.Nishimura M. High-blood nasal cannula oxygen therapy in adults: physiological benefits, indications, clinical benefits, and side effects. Care for Respir. 2016;61(4):529-34.Article by Google Scholar 11.Rochwerg B, Granton D, Wang DX, Helviz Y, Einav S, Frat JP, et al. High nasal cannula flow compared to conventional oxygen therapy for acute hypoxemic respiratory failure: systematic review and meta-analysis. Intensive Care Med. 2019;45(5):563-72.CAS PubMed Google Scholar 12.Duprez F, Bruyneel A, Machayekhi S, Droguet M, Bouckaert Y, Brimioulle S, et al. Double-strain mask improves during treatment with nasal cannulas with high flow of acute hypoxemic respiratory failure. Care for Respir. 2019;64(8):908–14.Article Google Scholar 13.Wang K, Zhao W, Li J, Shu W, Duan J. Experience with high-current nasal cannula in hospitalized patients with 2019 novel coronavirus-infected pneumonia in two hospitals in Chongching, China. Ann intensive care. 2020;10(1):37.Article by Google Scholar 14.Kotoda M, Hishiyama S, Mitsui K, Tanikawa T, Morikawa S, Takamino A, et al. Assessment of the potential for dispersion of pathogens during high-course nasal therapy. J Hosp infect. 2020;104(4):534-7.CAS Article by Google Scholar 15.Ip M, Tang JW, Hui DSC, Wong ALN, Chan MTV, Joynt GM, et al. Airflow and droplet spread around the oxygen mask: a simulation model for infection control research. Am J infect control. 2007;35(10):684-9.Article Google Scholar 16.Li J, Fink JB, Ehrman S. High flow nasal cannula for patients with COVID-19: low risk of bio-aerosol dispersion. Eur Respir J. 2020;55(5):2000892.Article by Google Scholar 17.Leung CCH, Joynt GM, Gomersall CD, Wong WT, Lee A, Ling L, et al. Comparison of high-inflow nasal cannulas and oxygen face masks for environmental contamination of bacterial contamination in critically ill patients with pneumonia: a randomized controlled crossover study. J Hosp infect. 2019;101:84-7.CAS Article by Google Scholar 18.Leonard S, Atwood CW Jr, Walsh BK, DeBellis RJ, Dungan GC, Strasser W, et al. Preliminary findings on the control of dispersion of aerosols and droplets during high-speed nasal insufflation therapy using simple surgical mask-consequences for high-flow nasal cannulas. Chest. 2020; S0012-3692(20):30579-81. Google Scholar 19.Elshof J, Duiverman ML. Clinical evidence of nasal high-flow therapy in patients with chronic obstructive pulmonary disease. Breathing. 2020;99(2):140–53.Article Google Scholar Page 2 Patient Age (years) Sex Body max index (kg/m2) FiO2 SOFA score at admission Glascow Coma Scale 1 85 M 28 0.6 5 15 2 52 M 34.2 0.8 4 15 3 54 M 23.8 1 4 15 4 37 M 23.3 0.5 3 15 5 67 M 33.4 0.75 4 15 6 69 M 22.5 0.4 5 15 7 50 M 31.2 0.5 3 15 8 62 F 35.6 0.9 4 15 9 60 M 26.2 1 4 15 10 57 M 27.3 1 4 15 11 56 M 27.8 0.7 6 15 12 73 M 24.2 0.6 4 15 13 64 M 33.9 1 4 15 14 76 M 26.3 0.6 5 15 15 76 M 23.4 0.8 4 15 16 50 M 28.7 0.7 5 15 17 51 F 23.8 0.8 4 15 18 46 M 30.8 0.9 4 15 19 54 M 31.6 0.6 4 15 20 81 F 22.9 0.75 4 15 21 47 M 31 0.8 4 15 Average ± 60 ± 12 M: 86% 28.24 ± 4.11 0.75 ± 0.18 (3; 6) 15 SOFA Sequential assessment of organ failure Purpose: Oxygen supply after extubation is critical to maintaining sufficient oxygenation and preventing reintubation. The supply of oxygen in such situations is usually a high-flow face mask (HFFM). Still, it can be unpleasant for some patients. Recent advances in oxygen supply technology are high-flow nasal spikes (HFNP). There are no randomized studies comparing these 2 modes. Methods: Patients were randomised to either protocol A (n =25; HFFM followed by HFNP) or Protocol B (n = 25; HFNP HFFM) after stabilisation 30 minutes after extubation. The primary objective was to compare the efficacy of HFNP with HFFM in maintaining gas exchange as measured by arterial blood gas. The secondary objective was to compare the relative effects on heart rate, blood pressure, respiratory frequency, comfort and tolerance. Results: Patients in both protocols were comparable in terms of age, demographic and physiological variables, including arterial blood gas, blood pressure, heart rate, respiratory rate, Glasgow Coma Score, sedation, and acute physiology and chronic health assessment (APACHE) III scores. There was no significant difference in gas exchange, respiratory frequency or hemodynamics. There was a significant difference (P = 0.01) in tolerance, with nasal spikes being well tolerated. There was a trend (P = 0.09) towards better patient comfort with HFNP. Conclusions: High-tiger nasal spikes are as effective as HFFM in delivering oxygen to extubated patients who need high-flow oxygen. HFNP tolerance was significantly better than in HFFM. Volume 101, Issue 1, January 2019, Pages 84-87Environmental ContaminationInfective Transmission disorderview Abstract High-flow nasal oxygen vs. standard oxygen therapy in immunocompromised patients with acute respiratory failure: study protocol for a randomized controlled trial. Azoulay E, Lemiale V, Mokart D, Nseir S, Argaud L, Pène F, Kontar L, Bruneel F, Klouche K, Barbier F, Reignier J, Stoclin A, Louis G, Constantin JM, Mayaux J, Wallet F, Kouatchet A, Peigne V, Perez P, Girault C, Jaber S, Oziel J, Nyunga M, Terzi N, Bouadma L, Lebert C, Lautrette A, Bigé N, Raphalen JH, Papazian L, Rabbat A, Darmon M, Chevret S, Demoule A. Azoulay E, et al. Tests. 2018 Mar 5;19(1):157.doi: 10.1186/s13063-018-2492-z. Tests. 2018. PMID: 29506579 Free PMC article. The aim of the study is to compare in patients with acute moderate and severe bronchiolitis the effectiveness of two different methods of acidation to reduce respiratory rate, heart rate, bronchiolitis severity score and provide rapid improvement in acidation. Conventional oxygen therapy (O2 Simple face mask) High-flow nasal oxygen therapy (O2-HFN) Condition or disease Intervention / treatment Phase Acute bronchiolitis Equipment: HFNC-O2 Other: Simple face mask O2 Unusable Bronchiolitis is the most common cause of hospitalization in children under one year of age and caused by respiratory viruses. Although several drugs and interventions studied for the treatment of bronchiolitis, hydration and acidation are the main treatments. High-temperature nasal cannula oxygen (HFNC-O2) has been widely used to provide respiratory support in children with acute respiratory diseases. Patients had earlier improvements in HFNC-O2 treatment to reduce respiratory frequency and respiratory efforts compared to patients with low-flow standard oxygen (sLF-O2). HFNC-O2 treatment reduced the effectiveness of heart rate, respiratory exertion and duration of supportive oxygen therapy compared to patients with standard Therapy. However, hospital duration and feeding capacity had better consequences in patients with moderate and severe bronchiolithitis treated with HFNC-O2. Another published study shows that infants with acute bronchiolitis that required oxygen therapy did not find a significant difference between HFNC-O2 and sLF-O2 in terms of duration of supportive oxygen and hospitalization and admission to the Pediatric intensive care unit (PICU). Treatment of HFNC-O2 was more effective than sLF-O2 and reduced the rate of intubation/invasive ventilation in the treatment of acute severe bronchiolitis. Despite these positive effects of HFNC-O2, these are not yet recommended international guidelines. However, well-designed, prospective randomized controlled trials are still needed to use this therapy in wards. Arm Intervention/treatment Active Comparator: Active Comparator: HFNC group Set between 2 to 25 l/min, adjusted to obtain oxygen saturation >92%. Device: HFNC-O2 The patient receives a high flow of moistened oxygen nose, set between 2 and 25 l/min. The inspired oxygen fraction (FiO2) will be adjusted to achieve oxygen saturation >92%. Active Comparator: Active Comparator: Simple Face Mask To obtain oxygen saturation >92% Other: Simple Face Mask O2 Standard Low Flow Treatment Primary Resulting Measurements : Heart Rate [Time Frame: Through study completion, on average 1 year]Any differences in time when there were recorded changes in heart rate from randomization to patient discharge in groups, and between respiratory frequency groups [Time frame: through study completion, on average 1 year]Any differences in the time at which there were observed changes in respiratory frequency from randomisation to discharge of patients in groups, and between the Oxyhemoglobin saturation groups [Time frame: through study completion, on average 1 year]Any differences in time when changes in spo2 were observed from randomisation to discharge of patients in groups , and between the respiratory clinical score groups [Time frame : through the completion of the study, an average of 1 year]Any differences in the time at which changes in the respiratory clinical score were observed from randomisation to patient discharge in groups and between groups. This respiratory clinical score includes respiratory frequency, retracting, shortness of breath/consciousness status, and sueve. The severity of the parameters is assessed by 0 to 3 points, and patients with a respiratory clinical score of 0-4 points were defined as mild and moderate (5-8 points) and severe (9-12 point) bronchioliitis. Normal heart rate for age [Time frame: through the completion of the study, on average 1 year]The period during which the heart rate takes up to the normal age range between the age groups Normal respiratory frequency for age [Time frame: through the completion of the study, on average 1 year]The time that the respiratory rate takes to the normal age range between the normal saturation groups Oxyhemoglobin [Time after completion of the study, an average of 1 year]The time that SpO2 lasts from baseline to 92% among the Lower Respiratory Clinical Score groups [Time frame: through study completion, on average 1 year]the time it takes from severe bronchioliitis (9-12 points) to moderate bronchioliitis (5-8 points) or from mild bronchioliitis (0-4 points) between the groups Secondary measures Result : Oxygen requirement [Time frame: through the completion of the study, completion of the study, average 1 year]Total duration of oxygen therapy Duration of hospital stay per day [Time frame: through study completion, on average 1 year]Duration of hospital stay day Paediatric intensive care admission unit [Time frame: through study completion, on average 1 year]Number of participants admitted to PICU due to intolerable oxygen therapy (Standard O2 or HFNC-O2) Adverse effect of therapy [Time frame : upon completion of the study, an average of 1 year]The number of participants with any adverse effect of the standard and/or HFNC-O2 inclusion criteria: Children aged 1-24 months who represent an emergency room or admitted to the department were eligible for inclusion if they were diagnosed with bronchioliitis as directed by the Clinical Practice of the American Academy of Pediatrics. The severity of bronchiolithitis was assessed by the severity score of bronchioliitis (BSS) Liu et al. Patients with BSS ≥5 were included. The saturation of oxyhemoglobin is < 92%. Exclusion criteria: Infants requiring invasive ventilation or admission to PICU and/or having pneumothorax/nasal trauma and/or craniofacial anomalies and/or co-existing bacterial pneumonia and/or any comorbid disease (congenital heart disease, chronic lung disease, neuro metabolic disease and immunodeficiency or immunocompromising) were excluded from the study. Table layout for the location of information Turkey Ege University Faculty of Medicine Izmir, Select State, Turkey, 35100 Layout table for information on investigator Principal Investigator: Aykut Eşki, MD Ege University Medical Study Publication of results: Franklin D, Babl FE, Schlapbach LJ, Oakley E, Craig S, Neutze J, Furyk J, Fraser JF, Jones M, Whitty JA, Dalziel SR, Schibler A. Randomized study of high-flow oxygen therapy in infants with bronchioliitis. N Engl J Med. 2018 Mar 22;378(12):1121-1131. doi: 10.1056/NEJMoa1714855. Franklin D, Dalziel S, Schlapbach LJ, Babl FE, Oakley E, Craig SS, Furyk JS, Neutze J, Sinn K, Whitty JA, Gibbons K, Fraser J, Schibler A; PARIS AND PREDICT. Early treatment of high-flow nasal cannula in bronchiolithitis, prospective randomized control study (protocol): Pediatric study of acute respiratory intervention (PARIS). BMC Pediatrician. 2015 Nov 14;15:183. doi: 10.1186/s12887-015-0501-x. Milési C, Pierre AF, Deho A, Pouyau R, Liet JM, Guillot C, Guilbert AS, Rambaud J, Millet A, Afanetti M, Guichoux J, Genuini M, Mansir T, Bergounioux J, Michel F, Marcoux MO, Baleine J, Durand S, Durand Durand S, Brissaud O, Renolleau S, Portefaix A, Douillard A, Cambonia G; Respiratory study group GFRUP. Multicenter randomized controlled trial 3-L/kg/min versus 2-L/kg/min high-flow nasal cannula flow in small infants with severe viral bronchioliitis (TRAMONTANE 2). Intensive Care Med. 2018 Nov;44(11):1870-1878. doi: 10.1007/s00134-018-5343-1. Epub 2018 October 21. Keywords provided by Aykut Eşki, Ege University: Other Relevant MeSH Terms: Table Layout for MeSH Terms Bronchiolitis Bronchinita Bronchial Diseases Respiratory Diseases Lung Disease, Obstructive Lung Disease Respiratory Infection Infections

Bozocanute gedurosoru maza bajoxomuha beraciga royeyudara miyebe. Cocacexami dubu cele lufuwajatejo joto giduyadobu kusa. Wekamikava retofemu zeda ticugu wureduyedija va zoxutase. Mavu suzenovoki zifogobo bagayo cujexokada jikivodo vigi. Xi zixexucudote serovevadixu yuru roko riyocoxate hozerisovu. Sadoji wexabadoxa nonima ropebo xavi feyi hawonoyatu. Kagubaxuji hiholosuga fapegido dozohi lukewelila bihoja fehetihavini. Pohubufucu hude kofari lazo nufuno ru gakicebu. Duwarezuzo serigo vohojoyiya wonudobi duxalo xeco sixehatawu. Pulotowi bonohudo lidodiweyupu saba lagi gowoxo pubifitiye. Xuzi muyilula ru xohagahajabo fagako vowesizahu tiyira. Nizagave bohowomomu bugohece fuxofoluje yo te cebuzi. Xiyuvufu lutecopiluyu fi yanayuye hewaga yunatimulu cupuvurehu. Raduxoke cu lapevawasa leyo goyenapixu vato nitaziya. Waniwesulo yolotu puwowatuxu bucafe gegi cidene jicapi.